Drug news
FDA approves Evista generic from Teva
Teva Pharmaceutical Industries Ltd. has announced the approval of the generic equivalent to Evista (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days. Evista 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximately $824 million in the United States, according to IMS data as of December 2013. Patent expires this month.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins